Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment

Age-related macular degeneration (AMD) is a chronic and progressive disease of the central retina that causes vision loss in people over 50 years of age. With an understanding of the role of VEGF in AMD, intravitreal anti-VEGF agents are used as the most important therapeutic tool in the management of AMD. In this review we try to discuss intravitreal ranibizumab treatment and treatment regimens in wet (neovascular) age-related macular degeneration.

Download Full-text

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration

ISRN Ophthalmology ◽

10.5402/2011/916789 ◽

2011 ◽

Vol 2011 ◽

pp. 1-4 ◽

Cited By ~ 1

Author(s):

Kisaburo Yamada ◽

Kenichi Kimoto ◽

Hirofumi Kono ◽

Toshiaki Kubota

Keyword(s):

Macular Degeneration ◽

Intravitreal Bevacizumab ◽

Age Related Macular Degeneration ◽

Rank Test ◽

Intravitreal Ranibizumab ◽

Age Related ◽

Signed Rank ◽

Significant Difference ◽

Signed Rank Test ◽

Ranibizumab Treatment

Purpose. To report our experiences in patients with age-related macular degeneration (AMD) treated initially with intravitreal ranibizumab and then switched to bevacizumab. Methods. We retrospectively reviewed the records of 7 patients (7 eyes) who were treated with monthly injections of intravitreal ranibizumab and then switched to injections of bevacizumab (every 6 weeks) for six months. The best-corrected visual acuity measurements (BCVA) and optical coherence tomography (OCT) were performed at the baseline examination and then at each visit. The Wilcoxon signed-rank test was used for the statistical analysis. Results. Following three monthly ranibizumab treatments, there was no significant difference in the BCVA, while the foveal retinal thickness (FRT) significantly decreased (). Switching from ranibizumab to bevacizumab resulted in maintenance (57.2%) of the BCVA and a further decrease in the FRT () after 6 months. Conclusions. Switching to intravitreal bevacizumab may be effective in patients who wish to discontinue intravitreal ranibizumab treatment due to the high cost.

Download Full-text

Long term intravitreal ranibizumab treatment for exsudative age-related macular degeneration

Orvosi Hetilap ◽

10.1556/oh.2013.29729 ◽

2013 ◽

Vol 154 (45) ◽

pp. 1790-1797 ◽

Cited By ~ 1

Author(s):

Regina Lukács ◽

Miklós Resch ◽

András Papp ◽

Antal Szabó ◽

Ágnes Borbándy ◽

...

Keyword(s):

Macular Degeneration ◽

Retinal Thickness ◽

Age Related Macular Degeneration ◽

Central Retinal Thickness ◽

First Year ◽

Intravitreal Ranibizumab ◽

Age Related ◽

Pro Re Nata ◽

Ranibizumab Treatment

Introduction: The results of intravitreal ranibizumab treatment for exsudative age-related macular degeneration have been favourable until this time. Aim: To evaluate the two-year functional and anatomic results of intravitreal ranibizumab treatment. Method: 46 patients (age: 75±9.1 years) were included in a prospective single center study. Treatment regimen was the following: monthly 0.5 mg ranibizumab was administered in the first 3 months, and later as required (pro re nata). The change of best corrected visual acuity and central retinal thickness was followed. Results: The visus change at the end of the follow-up time was not statistically significant compared to baseline (p = 0.760) and the at the end of the first year (p = 0.154). Central retinal thickness decreased significantly compared to baseline (p = 0.000001), but the change was not statistically significant compared to the end of the first year (p = 0.875). Conclusions: Patients with neovascular macular degeneration treated with intravitreal ranibizumab using pro re nata regimen have stable visus for long term, and the exsudation could be reduced efficiently. Orv. Hetil., 154(45), 1790–1797.

Download Full-text